Compare Incyte Corporation (INCY) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Main Street Capital Corporation — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Main Street Capital Corporation trades at $54.73 (market cap $5.08B). The key difference: Incyte Corporation is far larger — about 4.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.02% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MAIN | |
|---|---|---|
Market Cap | $23.11B | $5.08B |
Sector | Health | Financials |
52-Week High | $118.52 | $67.54 |
52-Week Low | $67.38 | $49.63 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 8.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Main Street Capital (MAIN) trades at $54.59, down 1.41% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.93, missing expectations of $1.01, while Q4 2025 beat estimates. Revenue for 2025 was $591.85M with a net income margin of 83.36%, though 2026 projections show a decline to $526M. Analysts maintain a consensus price target of $57.75 with a 'Hold' rating predominance. Recent news highlights MAIN's dividend sustainability amid softening earnings.
MAIN offers a stable dividend yield but faces earnings pressure and revenue decline projections for 2026. The stock's valuation appears reasonable with a P/E of 11.66, yet investor caution is warranted due to mixed earnings performance and potential headwinds from Fed rate cuts impacting BDC earnings. Upside exists if the company meets or exceeds future EPS expectations, supported by its internal management cost advantage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
